Tarlatamab is a bispecific monoclonal antibody and T-cell engager targeting delta-like ligand 3 (DLL3) and CD3 to treat extensive-stage small cell lung cancer. It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells and delta-like ligand 3 (DLL3), an inhibitory ligand that suppresses Notch signaling and is highly expressed across various SCLC disease...
- Mechanism
- Curator reviewed · 3 references
Tarlatamab is a bispecific monoclonal antibody and T-cell engager. It is directed at both delta-like ligand 3 (DLL3) expressed on cell surfaces and CD3 expressed on the surface of T-cells. DLL3 is an inhibitory ligand that suppresses Notch signaling which is aberrantly expressed on the surface of up to 85% of SCLC cells and minimally expressed in normal tissues, making it a compelling therapeutic target.
Tarlatamab serves to recruit and direct T-cells towards tumor cells expressing DLL3, resulting in T-cell activation and the release of inflammatory cytokines ultimately causing lysis of DLL3-expressing cells.
- Primary indication
- Tarlatamab is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.Curator reviewed · 1 structured indication
- Formula / weight
- 105000.0 Da
- First approval
- Canada, 2024 · United States, 2024
- Code names
- AMG-757
- Brand names
Resolves to
What you can answer from here — as of September 25, 2025
Which drugs share a target with Tarlatamab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account